Business Context and Reporting Period
This Form 8-K is a current report filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) on December 3, 2014, regarding an event that occurred on December 2, 2014. The filing addresses corporate governance changes under Item 5.02.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to director compensation:
- Annual Retainer: $10,000 (pro-rated).
- Meeting Fees: $2,000 per in-person meeting; $500 per telephonic meeting.
- Equity Grant: 30,000 options to purchase common stock.
Material Changes
The primary material change is the appointment of Richard Rodgers as a director of the Company, effective December 2, 2014. His term will last until the 2015 annual meeting of stockholders or until his successor is elected. Mr. Rodgers brings significant experience as a former CFO of oncology-focused biopharmaceutical companies, including TESARO and Abraxis BioScience.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business strategy, or discussion of risks and contingencies. The document is strictly limited to the appointment of a new director and the associated compensatory arrangements.
Investor Verification Checklist
- Verify the correct registrant name is Rexahn Pharmaceuticals, Inc., not Opus Genetics, Inc.
- Confirm the effective date of Richard Rodgers' board appointment (December 2, 2014).
- Review the specific terms of the 30,000 stock options granted to Mr. Rodgers in the full exhibit.
- Check subsequent filings for the 2015 annual meeting results to confirm if Mr. Rodgers was re-elected.